Black checkmark with a sparkle and a curved line underneath on a white background.
Company

BioScience Health Innovations, Inc.

Ticker
BHIC
Sector
Industry
Report date
November 14, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent news coverage includes general market and industry topics but does not directly pertain to BioScience Health Innovations, Inc.'s business activities or financial performance.

Recent developments:
  • Soybeans posted gains following export announcements, reflecting commodity market movements [N1].
  • Soybeans continued to pop higher on Friday after export announcements, indicating ongoing market activity [N2].
  • Tariffs have pushed prices up, with retail and industrial investors advised not to expect a quick reversal [N3].
  • Arrive AI provided three key takeaways for long-term investors, highlighting AI sector insights [N4].
  • Novo Nordisk secured EU approval for FREHEMGO in Haemophilia A, marking a regulatory milestone in biopharma [N5].
  • COSCIENS Biopharma Inc. reported a widened Q3 loss, indicating financial challenges in the sector [N6].
  • Alphamin Resources Corp. reported profit climbs in Q3, showing positive financial results in mining [N7].
  • Tron added $2.2 billion in stablecoins in July, reflecting activity in the cryptocurrency market [N8].
Overview

BioScience Health Innovations, Inc. operates as a development-stage company with a focus on acquiring and operating a viable business. The company is a voluntary filer with the SEC and provides quarterly and annual financial disclosures. As of the latest filings, the company reported revenues and incurred net losses, reflecting ongoing operating expenses and investment in business development. The company’s capital structure includes common stock and Series A Convertible Preferred Stock. It faces challenges typical of microcap and penny stock companies, including limited liquidity, market volatility, and regulatory compliance requirements.

Executive summary

BioScience Health Innovations, Inc. is a Nevada-based company that files periodic reports with the SEC, including a recent 10-Q for the quarter ended September 30, 2026. The company reported revenues of $970,071 and a net loss of $149,225 for that quarter. It holds cash and cash equivalents of approximately $1.69 million and total current assets of about $3.01 million as of September 30, 2026. The company’s common stock trades on the OTC Pink Market and is subject to penny stock regulations, which affect liquidity and marketability. The company faces risks related to limited capital, potential dilution, and regulatory constraints. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for BHIC

Bull case model:

The company has demonstrated the ability to generate revenues and maintain cash reserves, which supports ongoing operations and potential business development. Its filing status and compliance with SEC reporting provide transparency to investors. The increase in stockholders' equity over recent periods indicates capital infusion and potential growth in shareholder value. The company’s efforts to acquire an operating business could lead to the establishment of a sustainable business model.

Bear case model:

The company has reported net losses and negative earnings per share, reflecting ongoing operating expenses that exceed revenues. Its limited capital base and reliance on future financing pose risks of dilution and financial instability. The common stock’s trading on the OTC Pink Market and penny stock designation limit liquidity and marketability, potentially depressing stock price and investor interest. Regulatory changes and compliance costs may further strain resources. The company’s lack of a current operating business increases uncertainty about its future prospects.

Moat:

The company currently does not disclose a specific competitive moat or proprietary technology in its filings. Its status as a development-stage company suggests that it is in the process of establishing its business model and competitive positioning. The limited operating history and ongoing efforts to acquire an operating business imply that the company’s moat, if any, is not yet established or disclosed.

Risks overview
Risks summary
The company’s biggest risks stem from its limited capital, need for additional financing, regulatory compliance requirements, and the necessity to acquire an operating business to sustain its stock market listing and develop operations.
Risks details:

• Limited Capital and Financing Risk: The company has limited capital and may need to raise additional funds through debt or equity, which could dilute existing shareholders or impose unfavorable terms.
• Market Liquidity and Volatility: Trading in the company’s common stock is limited and sporadic, with the stock classified as a penny stock, leading to reduced liquidity and potential price volatility.
• Regulatory and Compliance Risks: Changes in SEC rules and OTC market regulations require the company to maintain current public information and may increase compliance costs or affect stock quotation status.
• Dilution Risk: Future issuances of common stock or convertible securities could dilute existing shareholders’ interests and affect stock price.
• Acquisition and Business Development Risk: The company must acquire an operating business within prescribed timeframes to maintain its stock quotation and develop a viable business model; failure to do so could adversely affect operations and stock value.

FINAL FORECAST FOR BHIC

Final take one line
BioScience Health Innovations, Inc. is a development-stage company with detailed SEC disclosures, facing typical microcap risks including limited capital, liquidity constraints, and the need to acquire an operating business.
Final take 12 to 24 month view

Business trends: The company is focused on acquiring and developing an operating business while managing limited revenues and ongoing losses.
Execution milestones: Maintaining SEC compliance, managing liquidity, and completing an acquisition to sustain OTC Pink Market listing.
Key risks: Capital constraints, dilution risk, regulatory compliance burdens, limited market liquidity, and volatility associated with penny stock status.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • BioScience Health Innovations, Inc. is a Nevada-incorporated company with its principal executive offices in Bluffdale, Utah.
  • The company is a voluntary filer with the SEC and files Forms 10-K and 10-Q, providing periodic financial disclosures.
  • As of September 30, 2026, the company had cash and cash equivalents of $1,691,858 and total current assets of $3,007,651 USD.
  • The company reported revenues of $970,071 for the three months ended September 30, 2026, and $2,757,381 for the nine months ended September 30, 2026.
  • Net loss for the three months ended September 30, 2026 was $149,225, with a basic and diluted loss per share of $0.01.
  • The company had total stockholders' equity of $2,922,712 as of September 30, 2026, up from $1,477,330 at December 31, 2025.
  • The company has issued 12,027,217 shares of common stock outstanding as of November 12, 2026.
  • The company has Series A Convertible Preferred Stock with 140,000 shares issued and outstanding as of September 30, 2026.
  • Operating expenses for the three months ended September 30, 2026 were $785,824, including general and administrative expenses of $720,121 and consulting fees of $65,703.
  • The company reported a gross profit of $637,564 for the three months ended September 30, 2026.
  • The company is not currently a party to any material legal proceedings or governmental regulatory proceedings.
  • The company faces risks related to limited capital, potential dilution from future equity issuances, limited market liquidity for its common stock, and regulatory constraints due to its penny stock status.
  • The company must acquire an operating business within prescribed timeframes to maintain its OTC Pink Market quotation.
  • The company’s common stock trades on the OTC Pink Market and is subject to penny stock rules, which limit liquidity and broker-dealer recommendations.
  • The company’s stock price may be volatile due to limited trading volume and other market factors.
  • The company’s financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-30 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-14 | www.nasdaq.com | Soybeans Post Friday Gains Following Export Announcements | https://www.nasdaq.com/articles/soybeans-post-friday-gains-following-export-announcements
  • N2 | 2026-11-14 | www.nasdaq.com | Soybeans Popping Higher on Friday Following Export Announcements | https://www.nasdaq.com/articles/soybeans-popping-higher-friday-following-export-announcements
  • N3 | 2026-11-14 | www.nasdaq.com | Tariffs Pushed Prices Up. Why Retail and Industrial Investors Shouldn't Expect a Quick Reversal | https://www.nasdaq.com/articles/tariffs-pushed-prices-why-retail-and-industrial-investors-shouldnt-expect-quick-reversal
  • N4 | 2026-11-14 | www.nasdaq.com | Arrive AI: 3 Key Takeaways for Long-Term Investors | https://www.nasdaq.com/articles/arrive-ai-3-key-takeaways-long-term-investors
  • N5 | 2026-11-14 | www.nasdaq.com | Novo Nordisk Secures EU Approval For FREHEMGO In Haemophilia A | https://www.nasdaq.com/articles/novo-nordisk-secures-eu-approval-frehemgo-haemophilia
  • N6 | 2026-11-14 | www.nasdaq.com | COSCIENS Biopharma Inc. Q3 Loss Widens | https://www.nasdaq.com/articles/cosciens-biopharma-inc-q3-loss-widens
  • N7 | 2026-11-14 | www.nasdaq.com | Alphamin Resources Corp. Profit Climbs In Q3 | https://www.nasdaq.com/articles/alphamin-resources-corp-profit-climbs-q3
  • N8 | 2026-08-09 | www.nasdaq.com | Tron Just Added $2.2 Billion in Stablecoins in July. Does That Make It a Buy? | https://www.nasdaq.com/articles/tron-just-added-22-billion-stablecoins-july-does-make-it-buy
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine